EDITEditas Medicine, Inc.
Price
-28%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
Editas Medicine, Inc. (EDIT) reported revenue of $12M in Q2 2026 (quarter ended Jun 30, 2026), up 232% from the same quarter a year earlier. That came with net loss of $18M. For the full year FY2025, revenue was $41M (+25% year on year) and net income −$160M. The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026On October 8, 2026, the Company announced that it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia.Regulation FD disclosure · Form 8-K
- Aug 5, 2026On August 3, 2026, Elliott Levy, M.D., a member of the Board of Directors (the “Board”) of the Company who was serving as a class I director, resigned from the Board, effective August 4, 2026.Earnings release · Form 8-K
- May 26, 2026Public Offering On May 26, 2026, Editas Medicine, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC as representatives of the underwriters named therein (the “Underwriters”), relating to an underwritten public …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.